BRPI0411863A - derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos - Google Patents
derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmosInfo
- Publication number
- BRPI0411863A BRPI0411863A BRPI0411863-4A BRPI0411863A BRPI0411863A BR PI0411863 A BRPI0411863 A BR PI0411863A BR PI0411863 A BRPI0411863 A BR PI0411863A BR PI0411863 A BRPI0411863 A BR PI0411863A
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- pharmaceutical compositions
- kinase inhibitors
- indole derivatives
- pyrazolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
"DERIVADOS DE PIRAZOLIL-INDOL COMO INIBIDORES DE CINASE, PROCESSO PARA SEU PREPARO E COMPOSIçõES FARMACêUTICAS COMPREENDENDO OS MESMOS". A presente invenção refere-se a derivados de pirazolindol da fórmula (I), conforme definido na especificação, e sais farmaceuticamente aceitáveis dos mesmos, processo para seu preparo e composições farmacêuticas compreendendo os mesmos são descritos, os compostos da invenção podendo ser úteis em terapia, no tratamento de doenças associadas a uma atividade desregulada de cinase de proteína, tal como câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48540603P | 2003-07-08 | 2003-07-08 | |
PCT/EP2004/007479 WO2005005414A2 (en) | 2003-07-08 | 2004-07-08 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411863A true BRPI0411863A (pt) | 2006-08-08 |
Family
ID=34062075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411863-4A BRPI0411863A (pt) | 2003-07-08 | 2004-07-08 | derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050032869A1 (pt) |
EP (1) | EP1648884A2 (pt) |
JP (1) | JP2009501126A (pt) |
BR (1) | BRPI0411863A (pt) |
CA (1) | CA2531751A1 (pt) |
MX (1) | MXPA06000302A (pt) |
WO (1) | WO2005005414A2 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US7572914B2 (en) * | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
EP1761539A1 (en) * | 2004-06-02 | 2007-03-14 | Takeda Pharmaceutical Company Limited | Indole derivative and use for treatment of cancer |
EP1781653A1 (en) * | 2004-07-05 | 2007-05-09 | Astex Therapeutics Limited | 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |
WO2006023931A2 (en) * | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
US7713973B2 (en) * | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
AU2005321091B2 (en) | 2004-12-30 | 2012-04-12 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases |
WO2006133885A1 (en) * | 2005-06-15 | 2006-12-21 | F. Hoffmann-La Roche Ag | Tricyclic fused indole derivatives and their use as aurora kinase inhibitors |
KR20080035691A (ko) | 2005-08-12 | 2008-04-23 | 제넨테크, 인크. | 펜타시클릭 키나제 억제제 |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
AU2006342024A1 (en) * | 2005-12-16 | 2007-10-25 | Genentech, Inc. | Tetracyclic kinase inhibitors |
US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008001115A2 (en) * | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
RU2480461C2 (ru) | 2006-11-16 | 2013-04-27 | Ф.И.С. Фаббрика Итальяна Синтетичи С.П.А. | Способ получения иматиниба и его промежуточных соединений |
JP2009001541A (ja) * | 2006-12-15 | 2009-01-08 | Ishihara Sangyo Kaisha Ltd | 新規ピラゾール化合物を中間体として用いるアントラニルアミド系化合物の製造方法 |
US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
KR101735868B1 (ko) * | 2010-02-17 | 2017-05-15 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소고리 화합물 |
JP5859640B2 (ja) | 2011-05-17 | 2016-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトンチロシンキナーゼ阻害剤 |
CN104640850A (zh) * | 2012-10-26 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂 |
CN103044311B (zh) * | 2012-12-26 | 2015-04-22 | 山东大学 | 一种多取代吲哚类化合物及其制备方法和应用 |
US10758530B2 (en) * | 2016-02-19 | 2020-09-01 | Phoenix Molecular Designs | Carboxamide derivatives useful as rsk inhibitors |
TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
TW201835070A (zh) * | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
AU2018368790A1 (en) | 2017-11-20 | 2020-06-25 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
CN111819193A (zh) | 2018-01-05 | 2020-10-23 | 西奈山伊坎医学院 | 增加胰腺β细胞增殖的方法、治疗方法以及组合物 |
US11866427B2 (en) | 2018-03-20 | 2024-01-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
AU2019418800A1 (en) * | 2018-12-31 | 2021-07-01 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
WO2021231474A1 (en) * | 2020-05-12 | 2021-11-18 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
WO2023098699A1 (en) * | 2021-12-01 | 2023-06-08 | Nanjing Immunophage Biotech Co., Ltd | Compounds and their uses as cd38 inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1274706A1 (en) * | 2000-04-18 | 2003-01-15 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
GB0102687D0 (en) * | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
US20020198252A1 (en) * | 2001-05-24 | 2002-12-26 | Joseph Payack | Process for the preparation of alkylamine substituted indoles |
US20040242559A1 (en) * | 2003-04-25 | 2004-12-02 | Aventis Pharma S.A. | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors |
-
2004
- 2004-07-01 US US10/882,492 patent/US20050032869A1/en not_active Abandoned
- 2004-07-08 WO PCT/EP2004/007479 patent/WO2005005414A2/en active Application Filing
- 2004-07-08 MX MXPA06000302A patent/MXPA06000302A/es unknown
- 2004-07-08 JP JP2006518139A patent/JP2009501126A/ja not_active Withdrawn
- 2004-07-08 BR BRPI0411863-4A patent/BRPI0411863A/pt not_active IP Right Cessation
- 2004-07-08 CA CA002531751A patent/CA2531751A1/en not_active Abandoned
- 2004-07-08 EP EP04763124A patent/EP1648884A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MXPA06000302A (es) | 2006-04-18 |
EP1648884A2 (en) | 2006-04-26 |
WO2005005414A3 (en) | 2005-04-21 |
CA2531751A1 (en) | 2005-01-20 |
JP2009501126A (ja) | 2009-01-15 |
US20050032869A1 (en) | 2005-02-10 |
WO2005005414A2 (en) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411863A (pt) | derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos | |
BRPI0410563A (pt) | derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase | |
BRPI0411868A (pt) | derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase | |
BRPI0507375A (pt) | derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase | |
BR0311291A (pt) | Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
EA201170249A1 (ru) | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ | |
BR0315988A (pt) | Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
BRPI0606313A2 (pt) | derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia | |
BR0307819A (pt) | Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais | |
NO20040547L (no) | Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse. | |
BR0312722A (pt) | Derivados de pirazol heterobicìclico como inibidores de qinase | |
BRPI0416989A (pt) | derivados aminopirazole como inibidores gsk-3 | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
BRPI0408486A (pt) | derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os | |
BRPI0411891A (pt) | pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3 | |
BRPI0411122A (pt) | pirazol[3,4-b]piridin-6-onas como inibidores gsk-3 | |
UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
BRPI0508706A (pt) | derivados de dicloro-fenil-pirido[2,3-d]pirimidina inusitados, sua fabricação e uso como agentes farmacêuticos | |
BR112023025042A2 (pt) | Pirrol[2,3-d]pirimidinas substituídas, preparação das mesmas e aplicação terapêutica das mesmas | |
UY28409A1 (es) | Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |